Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20

5:36

Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.

Diffuse Large B Cell Lymphoma
Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20

Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.

Diffuse Large B Cell Lymphoma Similar Videos

Similar Videos